Garrick Colin Stewart, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Heart-Assist Devices | 46 | 2024 | 1288 | 6.090 |
Why?
|
Heart Failure | 52 | 2024 | 11701 | 2.980 |
Why?
|
Heart Transplantation | 19 | 2024 | 3258 | 1.680 |
Why?
|
Heart Failure, Systolic | 5 | 2024 | 135 | 1.130 |
Why?
|
Defibrillators, Implantable | 8 | 2019 | 1492 | 1.060 |
Why?
|
Myocarditis | 5 | 2024 | 792 | 1.060 |
Why?
|
Registries | 17 | 2021 | 8247 | 0.770 |
Why?
|
Quality of Life | 15 | 2024 | 13367 | 0.670 |
Why?
|
Death, Sudden, Cardiac | 5 | 2015 | 1560 | 0.620 |
Why?
|
Cardiotonic Agents | 2 | 2020 | 540 | 0.590 |
Why?
|
Activities of Daily Living | 2 | 2019 | 2420 | 0.510 |
Why?
|
Assisted Circulation | 1 | 2015 | 100 | 0.500 |
Why?
|
Sarcoidosis | 5 | 2019 | 537 | 0.490 |
Why?
|
Ventricular Function | 1 | 2017 | 406 | 0.490 |
Why?
|
Shock, Cardiogenic | 3 | 2018 | 709 | 0.470 |
Why?
|
Cardiomyopathies | 6 | 2019 | 2021 | 0.440 |
Why?
|
Ventricular Function, Left | 5 | 2020 | 3899 | 0.410 |
Why?
|
Outpatients | 5 | 2019 | 1598 | 0.400 |
Why?
|
Stroke Volume | 5 | 2024 | 5521 | 0.370 |
Why?
|
Risk Assessment | 10 | 2021 | 24021 | 0.370 |
Why?
|
Parvovirus B19, Human | 1 | 2010 | 40 | 0.360 |
Why?
|
Primary Prevention | 2 | 2015 | 1185 | 0.360 |
Why?
|
Hemodynamics | 3 | 2018 | 4165 | 0.350 |
Why?
|
Ambulatory Care | 4 | 2018 | 2770 | 0.340 |
Why?
|
Thrombosis | 4 | 2019 | 2944 | 0.340 |
Why?
|
Chest Pain | 2 | 2013 | 1097 | 0.340 |
Why?
|
Prosthesis Implantation | 3 | 2020 | 590 | 0.330 |
Why?
|
Myocardium | 8 | 2017 | 4746 | 0.320 |
Why?
|
Heart Ventricles | 7 | 2020 | 3813 | 0.320 |
Why?
|
Ventricular Dysfunction, Left | 4 | 2016 | 2131 | 0.300 |
Why?
|
Severity of Illness Index | 8 | 2021 | 15841 | 0.300 |
Why?
|
Patient Selection | 7 | 2017 | 4246 | 0.300 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2018 | 1462 | 0.280 |
Why?
|
Tachycardia, Ventricular | 1 | 2015 | 1305 | 0.270 |
Why?
|
Humans | 73 | 2024 | 761208 | 0.260 |
Why?
|
Life Expectancy | 2 | 2009 | 1242 | 0.250 |
Why?
|
Postoperative Complications | 4 | 2015 | 15637 | 0.250 |
Why?
|
Cardiomegaly | 1 | 2008 | 590 | 0.250 |
Why?
|
Preoperative Care | 1 | 2014 | 2241 | 0.240 |
Why?
|
Physician-Patient Relations | 1 | 2017 | 3253 | 0.230 |
Why?
|
Decision Making | 1 | 2017 | 3931 | 0.220 |
Why?
|
Fluorodeoxyglucose F18 | 5 | 2019 | 2024 | 0.210 |
Why?
|
Palliative Care | 1 | 2018 | 3599 | 0.210 |
Why?
|
Adrenergic beta-Antagonists | 2 | 2019 | 1241 | 0.200 |
Why?
|
Prognosis | 9 | 2024 | 29687 | 0.200 |
Why?
|
Heart Atria | 1 | 2008 | 1349 | 0.200 |
Why?
|
Prosthesis Design | 4 | 2019 | 2114 | 0.190 |
Why?
|
Cardiac Resynchronization Therapy | 2 | 2019 | 558 | 0.190 |
Why?
|
Ventricular Remodeling | 1 | 2009 | 1270 | 0.190 |
Why?
|
Heart | 2 | 2013 | 4431 | 0.190 |
Why?
|
Angiotensin Receptor Antagonists | 2 | 2019 | 1039 | 0.190 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2019 | 1504 | 0.180 |
Why?
|
Male | 36 | 2024 | 360693 | 0.180 |
Why?
|
Patient Education as Topic | 2 | 2009 | 2317 | 0.170 |
Why?
|
Middle Aged | 30 | 2024 | 220853 | 0.170 |
Why?
|
Warfarin | 2 | 2018 | 1482 | 0.170 |
Why?
|
Female | 36 | 2024 | 392544 | 0.160 |
Why?
|
Treatment Outcome | 16 | 2023 | 64681 | 0.160 |
Why?
|
Aged | 24 | 2024 | 169288 | 0.160 |
Why?
|
Receptors, Somatostatin | 1 | 2019 | 137 | 0.150 |
Why?
|
Prospective Studies | 13 | 2021 | 54435 | 0.150 |
Why?
|
Disease Progression | 4 | 2018 | 13511 | 0.150 |
Why?
|
Aspirin | 2 | 2021 | 3129 | 0.150 |
Why?
|
Triage | 1 | 2024 | 985 | 0.140 |
Why?
|
Hydralazine | 1 | 2016 | 34 | 0.140 |
Why?
|
Heart Defects, Congenital | 1 | 2014 | 4673 | 0.140 |
Why?
|
Systole | 1 | 2018 | 936 | 0.130 |
Why?
|
Neprilysin | 1 | 2019 | 478 | 0.130 |
Why?
|
Health Status | 3 | 2020 | 4077 | 0.130 |
Why?
|
Blood Coagulation Factors | 1 | 2018 | 366 | 0.130 |
Why?
|
Diuretics | 1 | 2019 | 611 | 0.130 |
Why?
|
Telemetry | 1 | 2017 | 199 | 0.130 |
Why?
|
Organometallic Compounds | 1 | 2019 | 647 | 0.130 |
Why?
|
Sodium Potassium Chloride Symporter Inhibitors | 1 | 2016 | 152 | 0.120 |
Why?
|
Nitrates | 1 | 2016 | 260 | 0.120 |
Why?
|
Attitude to Health | 2 | 2017 | 2026 | 0.120 |
Why?
|
Ventricular Dysfunction, Right | 1 | 2020 | 629 | 0.120 |
Why?
|
Anticoagulants | 3 | 2019 | 4795 | 0.110 |
Why?
|
Time Factors | 9 | 2023 | 39957 | 0.110 |
Why?
|
Positron-Emission Tomography | 4 | 2019 | 6585 | 0.110 |
Why?
|
Phenotype | 1 | 2010 | 16575 | 0.100 |
Why?
|
Biopsy | 3 | 2017 | 6781 | 0.100 |
Why?
|
Selection Bias | 1 | 2014 | 359 | 0.100 |
Why?
|
Vasodilator Agents | 1 | 2016 | 989 | 0.100 |
Why?
|
Fatal Outcome | 2 | 2013 | 1838 | 0.100 |
Why?
|
Risk Factors | 9 | 2022 | 74239 | 0.090 |
Why?
|
Thromboembolism | 1 | 2018 | 992 | 0.090 |
Why?
|
Radiopharmaceuticals | 5 | 2019 | 2683 | 0.090 |
Why?
|
Parvoviridae Infections | 1 | 2010 | 36 | 0.090 |
Why?
|
Hypotension | 2 | 2013 | 879 | 0.090 |
Why?
|
Prevalence | 4 | 2020 | 15721 | 0.090 |
Why?
|
Retrospective Studies | 13 | 2023 | 80674 | 0.090 |
Why?
|
Arrhythmias, Cardiac | 1 | 2020 | 2247 | 0.090 |
Why?
|
Risk Adjustment | 1 | 2014 | 601 | 0.080 |
Why?
|
Electrocardiography | 4 | 2017 | 6387 | 0.080 |
Why?
|
Caregivers | 1 | 2021 | 2244 | 0.080 |
Why?
|
Risk | 3 | 2016 | 9616 | 0.080 |
Why?
|
Hospitalization | 5 | 2024 | 10707 | 0.080 |
Why?
|
Decision Support Systems, Clinical | 1 | 2018 | 1172 | 0.080 |
Why?
|
Graft Rejection | 2 | 2021 | 4481 | 0.070 |
Why?
|
Prosthesis-Related Infections | 1 | 2013 | 488 | 0.070 |
Why?
|
Cardiology | 1 | 2019 | 1693 | 0.070 |
Why?
|
Adipose Tissue | 1 | 2020 | 3313 | 0.070 |
Why?
|
Mortality | 1 | 2019 | 2896 | 0.070 |
Why?
|
Medical Oncology | 1 | 2019 | 2320 | 0.070 |
Why?
|
History, 21st Century | 1 | 2013 | 1567 | 0.070 |
Why?
|
Recovery of Function | 1 | 2017 | 2981 | 0.070 |
Why?
|
Stroke | 2 | 2020 | 9721 | 0.070 |
Why?
|
International Normalized Ratio | 2 | 2018 | 382 | 0.070 |
Why?
|
Terminal Care | 1 | 2018 | 1760 | 0.070 |
Why?
|
Patient-Centered Care | 1 | 2016 | 1427 | 0.070 |
Why?
|
History, 20th Century | 1 | 2013 | 2765 | 0.060 |
Why?
|
Cardiomyopathy, Hypertrophic | 1 | 2014 | 1312 | 0.060 |
Why?
|
Sex Factors | 1 | 2019 | 10553 | 0.060 |
Why?
|
Practice Guidelines as Topic | 2 | 2019 | 7400 | 0.060 |
Why?
|
Survival Rate | 3 | 2020 | 12728 | 0.060 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 3245 | 0.060 |
Why?
|
Myocardial Infarction | 3 | 2012 | 11476 | 0.060 |
Why?
|
Adult | 10 | 2020 | 221119 | 0.060 |
Why?
|
Chronic Disease | 1 | 2019 | 9319 | 0.060 |
Why?
|
Predictive Value of Tests | 2 | 2019 | 15308 | 0.060 |
Why?
|
Autoimmunity | 1 | 2012 | 1356 | 0.060 |
Why?
|
Magnetic Resonance Imaging | 4 | 2019 | 36415 | 0.060 |
Why?
|
DNA, Viral | 1 | 2010 | 2195 | 0.060 |
Why?
|
Attitude of Health Personnel | 1 | 2017 | 3885 | 0.050 |
Why?
|
Angina, Unstable | 1 | 2007 | 890 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 1 | 2014 | 6486 | 0.050 |
Why?
|
Cost of Illness | 3 | 2021 | 1936 | 0.050 |
Why?
|
Xanthine Oxidase | 1 | 2002 | 69 | 0.050 |
Why?
|
Aged, 80 and over | 7 | 2019 | 58952 | 0.050 |
Why?
|
Fatigue | 2 | 2021 | 1550 | 0.050 |
Why?
|
Exercise Test | 2 | 2021 | 2165 | 0.050 |
Why?
|
Diagnosis, Differential | 2 | 2013 | 12976 | 0.050 |
Why?
|
Viral Load | 1 | 2010 | 3328 | 0.050 |
Why?
|
Animals | 5 | 2018 | 168079 | 0.050 |
Why?
|
Medicare | 3 | 2015 | 6773 | 0.050 |
Why?
|
Anaerobic Threshold | 1 | 2021 | 51 | 0.050 |
Why?
|
Depression | 1 | 2020 | 8132 | 0.040 |
Why?
|
Diagnostic Imaging | 1 | 2014 | 3534 | 0.040 |
Why?
|
Motor Activity | 1 | 2009 | 2712 | 0.040 |
Why?
|
United States | 6 | 2020 | 72339 | 0.040 |
Why?
|
Nitric Oxide Synthase | 1 | 2002 | 908 | 0.040 |
Why?
|
Survivors | 1 | 2009 | 2369 | 0.040 |
Why?
|
Hand Strength | 1 | 2021 | 456 | 0.040 |
Why?
|
Cross-Sectional Studies | 2 | 2020 | 26071 | 0.040 |
Why?
|
Age Factors | 2 | 2014 | 18384 | 0.040 |
Why?
|
Comorbidity | 3 | 2020 | 10516 | 0.040 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2012 | 3417 | 0.040 |
Why?
|
Obesity | 1 | 2020 | 12939 | 0.040 |
Why?
|
Coronary Artery Disease | 1 | 2017 | 6505 | 0.040 |
Why?
|
Patient Satisfaction | 1 | 2009 | 3453 | 0.030 |
Why?
|
Radiography | 1 | 2008 | 6974 | 0.030 |
Why?
|
Frail Elderly | 1 | 2021 | 766 | 0.030 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2023 | 1116 | 0.030 |
Why?
|
Follow-Up Studies | 4 | 2020 | 39126 | 0.030 |
Why?
|
Bradycardia | 1 | 2017 | 298 | 0.030 |
Why?
|
Atrioventricular Block | 1 | 2017 | 133 | 0.030 |
Why?
|
Cardiomyopathy, Dilated | 1 | 2002 | 832 | 0.030 |
Why?
|
Bundle-Branch Block | 1 | 2017 | 277 | 0.030 |
Why?
|
Incidence | 3 | 2020 | 21365 | 0.030 |
Why?
|
Ultrasonography | 1 | 2008 | 5969 | 0.030 |
Why?
|
Syncope | 1 | 2017 | 428 | 0.030 |
Why?
|
Oxygen Consumption | 1 | 2021 | 1867 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 2019 | 14675 | 0.030 |
Why?
|
Drug Interactions | 1 | 2018 | 1417 | 0.030 |
Why?
|
Rubidium Radioisotopes | 1 | 2013 | 97 | 0.030 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2017 | 2746 | 0.030 |
Why?
|
Proportional Hazards Models | 3 | 2014 | 12474 | 0.030 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2017 | 1130 | 0.030 |
Why?
|
Postoperative Care | 1 | 2019 | 1468 | 0.020 |
Why?
|
Myocardial Perfusion Imaging | 1 | 2017 | 659 | 0.020 |
Why?
|
Regression Analysis | 1 | 2021 | 6345 | 0.020 |
Why?
|
Equipment Failure | 1 | 2013 | 580 | 0.020 |
Why?
|
Cohort Studies | 2 | 2014 | 41496 | 0.020 |
Why?
|
Organ Size | 1 | 2015 | 2253 | 0.020 |
Why?
|
Neoplasms | 1 | 2019 | 22140 | 0.020 |
Why?
|
Skilled Nursing Facilities | 1 | 2014 | 400 | 0.020 |
Why?
|
Prosthesis Failure | 1 | 2014 | 1204 | 0.020 |
Why?
|
Middle East | 1 | 2009 | 231 | 0.020 |
Why?
|
Diabetes Mellitus | 1 | 2007 | 5842 | 0.020 |
Why?
|
Perfusion | 1 | 2013 | 1390 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2019 | 5250 | 0.020 |
Why?
|
Dyspnea | 1 | 2016 | 1347 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2021 | 12052 | 0.020 |
Why?
|
Propensity Score | 1 | 2015 | 1916 | 0.020 |
Why?
|
Cause of Death | 1 | 2017 | 3688 | 0.020 |
Why?
|
Hemorrhage | 1 | 2018 | 3422 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2019 | 7804 | 0.020 |
Why?
|
Pilot Projects | 1 | 2019 | 8642 | 0.020 |
Why?
|
Hip Fractures | 1 | 2014 | 989 | 0.020 |
Why?
|
Coronary Angiography | 1 | 2017 | 4506 | 0.020 |
Why?
|
Echocardiography | 1 | 2017 | 5006 | 0.020 |
Why?
|
Adrenal Cortex Hormones | 1 | 2013 | 1878 | 0.010 |
Why?
|
Acute Disease | 1 | 2015 | 7226 | 0.010 |
Why?
|
Contrast Media | 1 | 2018 | 5311 | 0.010 |
Why?
|
Waiting Lists | 1 | 2009 | 766 | 0.010 |
Why?
|
Massachusetts | 1 | 2017 | 8837 | 0.010 |
Why?
|
Immunotherapy | 1 | 2019 | 4642 | 0.010 |
Why?
|
Autoantibodies | 1 | 2012 | 2119 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 8003 | 0.010 |
Why?
|
Young Adult | 2 | 2019 | 59221 | 0.010 |
Why?
|
Cooperative Behavior | 1 | 2009 | 1506 | 0.010 |
Why?
|
omega-N-Methylarginine | 1 | 2002 | 108 | 0.010 |
Why?
|
Hospital Mortality | 1 | 2015 | 5295 | 0.010 |
Why?
|
Free Radical Scavengers | 1 | 2002 | 211 | 0.010 |
Why?
|
Adolescent | 2 | 2019 | 88298 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2019 | 20119 | 0.010 |
Why?
|
Allopurinol | 1 | 2002 | 198 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2022 | 20588 | 0.010 |
Why?
|
Signal Transduction | 1 | 2002 | 23416 | 0.010 |
Why?
|
Ascorbic Acid | 1 | 2002 | 654 | 0.010 |
Why?
|
Cardiac Pacing, Artificial | 1 | 2002 | 866 | 0.010 |
Why?
|
Fluorescent Antibody Technique | 1 | 2002 | 2468 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2013 | 14610 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 2002 | 2217 | 0.010 |
Why?
|
Dogs | 1 | 2002 | 3832 | 0.010 |
Why?
|
Myocardial Contraction | 1 | 2002 | 1516 | 0.010 |
Why?
|
Survival Analysis | 1 | 2007 | 10088 | 0.010 |
Why?
|
Antioxidants | 1 | 2002 | 1667 | 0.010 |
Why?
|
Inflammation | 1 | 2013 | 10759 | 0.010 |
Why?
|
Energy Metabolism | 1 | 2002 | 2877 | 0.010 |
Why?
|
Mice | 1 | 2012 | 81326 | 0.000 |
Why?
|